Hematologic Malignancies
The sponsor is strongly involved in studies of multiple myeloma, acute lymphoblastic leukemia, non-Hodgkin lymphoma, follicular lymphoma, and AL amyloidosis, with a focus on treatment strategies for newly diagnosed, refractory, relapsed, and transplant-eligible disease.
- Minimal residual disease assessment
- Antibody-based therapy
- CAR T-cell therapy
- Maintenance treatment
Research activity also includes lymphoid diseases with emphasis on immune-targeted and cellular approaches.
Solid Tumors and Surgical Oncology
Clinical research spans colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, pancreatic ductal adenocarcinoma, and rare sarcomas such as synovial sarcoma and desmoplastic small round cell tumor.
- Neoadjuvant treatment
- Adjuvant chemotherapy
- Targeted antibody-drug conjugates
- Biomarker-guided therapy
Trials in this area also address treatment selection around surgery and resistance to systemic therapy.
Neuro-Oncology and Pediatric Brain Tumors
The sponsor supports research in glioblastoma, WHO grade 2 or 3 glioma, pediatric low-grade glioma, and other high-risk pediatric malignancies, including tumors with aggressive molecular features.
- Perioperative therapy
- Progressive glioma
- Immune-based combinations
- Childhood and adolescent oncology
Work in this field also includes outcomes related to neuropsychologic development and disease control in early-life neuro-oncologic conditions.
Rare Diseases and Immune-Mediated Disorders
Additional studies address cystic fibrosis, tuberous sclerosis complex, adrenal insufficiency, acromegaly, Takotsubo syndrome, and acute ischemic stroke, alongside other immune-mediated and endocrine conditions.
- Inflammation-related treatment
- Endocrine disorders
- Neurologic and cardiac injury
- Rare disease management
These trials include interest in myocardial injury, lung function, and metabolic disease across specialized patient groups.
Translational Medicine and Healthy Volunteer Research
The research portfolio also includes healthy volunteer studies and translational work on pharmacokinetics, microbiome interactions, and immune profiling relevant to oncology and other therapeutic areas.
- Drug disposition
- Immune signature analysis
- Microbiome-related effects
- Therapeutic response prediction
These studies support investigation of treatment response, exposure, and biologic variation across clinical settings.
